News
Gilead Sciences’ Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg tablets) has been approved by the ...
Gilead's Q2 earnings beat and raised 2025 outlook lift shares 7.3%, fueled by HIV gains, Trodelvy strength, and new PrEP ...
Gilead Sciences is a fantastic company that's revolutionized the treatment of numerous diseases. But click here to read why ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback